What is known and objective: Kaposi's sarcoma (KS) is a malignant neoplasm caused by HHV-8, a pathogen that leads to endothelial cell transformation when host defences are weakened. Case description: Here we report the first case of KS during treatment with abatacept, a biologic agent targeting T-cell costimulation. The patient was a 64-year-old female with rheumatoid arthritis who developed multiple firm, purple-reddish nodules on the dorsal aspect of the right hand. Histological examination confirmed KS. What is new and conclusion: Although a direct causal relationship between KS development and abatacept treatment cannot be proved, we hypothesize a role for costimulation blockade.
Olivo D., Grembiale R.D., Tallarigo F., Russo E., De Sarro G., Ursini F. (2017). Kaposi's sarcoma after T-cell costimulation blockade with abatacept in rheumatoid arthritis: a case report. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 42(3), 367-369 [10.1111/jcpt.12510].
Kaposi's sarcoma after T-cell costimulation blockade with abatacept in rheumatoid arthritis: a case report
Ursini F.
2017
Abstract
What is known and objective: Kaposi's sarcoma (KS) is a malignant neoplasm caused by HHV-8, a pathogen that leads to endothelial cell transformation when host defences are weakened. Case description: Here we report the first case of KS during treatment with abatacept, a biologic agent targeting T-cell costimulation. The patient was a 64-year-old female with rheumatoid arthritis who developed multiple firm, purple-reddish nodules on the dorsal aspect of the right hand. Histological examination confirmed KS. What is new and conclusion: Although a direct causal relationship between KS development and abatacept treatment cannot be proved, we hypothesize a role for costimulation blockade.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
